Zosano Pharma Corporation (ZSAN) Traders Should Start Listening to Analysts

Zosano Pharma Corporation (ZSAN) shares saw a recent bid of $1.26 and 1.24M shares have exchanged hands in the recent trading session, yielding a -19.23% decline over the past week. The stock price decreased -5.26% or $0.07 versus $1.33 at the end of the prior session. This change led market cap to move at $52.91M, putting the price -64.40% below the 52-week high and 178.76% above the 52-week low. The company’s stock has a normal trading capacity of 1.45M shares while the relative volume is 0.86.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $4.00 while $4.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $0 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $4.00, which would be an increase of about 217% of its current value. The mean target of $4.00 should be compared with the price when the stock was languishing around $0.45 a share. And it remains to be seen which target price ZSAN can achieve without sacrificing much as the company is holding a -16.56% fall for the past twelve months.

By historical standards, Zosano Pharma Corporation remains a cheap stock. The company’s current price-earnings ratio amounts above the average P/E ratio of 233.99 times earnings. For now, Zosano Pharma Corporation is the toast of Wall Street as its ABR stands at 2.00 with 0 out of 1 analysts rating the stock a buy. Over the short term, some market observers may have noticed that Zosano Pharma Corporation has a 10.54% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. Zosano Pharma Corporation has far performed well this year, with the share price up 61.54% since January. Over the past 2 quarters, the stock is up 40.00%, compared with a fall of nearly -26.74% for 3 months and about -7.35% for the past 30 days.

Revenue for the quarter also killed consensus, coming in at $0M, compared to the consensus of 0M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $-0.19. The company is expected to report EPS as high as $-0.19 and as low as $-0.19 per share. Similarly, full-year EPS forecasts have ranged between $-0.97 and $-0.97. The mean EPS estimate is $-0.97. On the other side, sales forecasts for the current quarter are $0M. The stock is expected to report revenue as high as $0M and as low as $0M per share. Similarly, full-year sales forecasts have ranged between $0M and $0M. The mean revenue estimate is $0M.

Over the last 5 years, Analysts are expecting EPS growth rates to be at 13.00% this quarter.




Sell-side analysts also have something to say about this company. Piper Jaffray analysts stated on 24/03/2017 that they launched coverage on this stock with Overweight rating. Ladenburg Thalmann had a markedly different take on 11/08/2016, proposing that Zosano Pharma Corporation is now considered Neutral versus prior Buy rating. ROTH Capital analysts stated on 11/11/2015 that they maintained their Buy rating. ROTH Capital analysts stated on 29/09/2015 that they maintained their Buy rating.

Leave a Reply

Your email address will not be published. Required fields are marked *